trusted by 100+ Patients
RGCC Immune Frame
Treatment Intro
What is RGCC Immune Frame?
The RGCC Immune Frame is an advanced diagnostic tool designed to assess the functionality of your immune system, particularly its ability to detect and combat cancer. This comprehensive test analyses a wide range of immune cells and markers, providing detailed insight into how your immune system is responding to disease and treatment.
Beyond monitoring response to cancer therapies, Immune Frame is also valuable as a baseline assessment before regenerative procedures, such as stem cell therapy. It helps identify immune imbalances and track improvements over time, allowing your healthcare provider to tailor and optimise your treatment plan for maximum efficacy.
Why to Choose it
Why Choose RGCC Immune Frame?
Early Detection of Immune Issues
Comprehensive Immune System Analysis
Personalized Cancer Treatment
Improves Immunotherapy Effectiveness
Non-Invasive & Easy to Use
Ongoing Monitoring
Boosts Immunotherapy Effectiveness
Cancer Recurrence Prevention
Supports Overall Immune Health
Perfect for
Is This Test Right for You?
FAQs
What is the RGCC Immune Frame used for?
The RGCC Immune Frame is a specialised cancer test that evaluates a patient’s immune system—specifically its ability to recognise and respond to tumor cells. It’s primarily used to help personalise cancer treatment, support immunotherapy, and track immune function over time.
Who should consider taking this test?
This test is recommended for:
- Cancer patients currently undergoing treatment
- Individuals considering or receiving immunotherapy drugs
- Survivors wanting to monitor their immune recovery
- People at high risk of developing cancer, including those with a family history or genetic predispositions
- Anyone looking to strengthen their immune system for long-term prevention and optimal health status
How does this test help with personalised cancer treatment?
The RGCC Immune Frame provides a detailed view of how your immune system is functioning, particularly in the context of cancer. By analysing immune cell activity, cytokine levels, and regulatory markers, it helps identify immune-related strengths and dysfunctions. These insights allow doctors to tailor cancer treatments more effectively—especially when considering immunotherapy or other targeted approaches—by selecting therapies that align with your immune system’s current capacity to respond.
What does the test measure in the immune system?
The test assesses:
- Levels of key immune cells like T-cells, B-cells, and Natural Killer (NK) cells
- Cytokine levels that regulate immune response
- Specific cellular markers that indicate immune function and balance
This analysis can identify specific cellular markers that reveal how the immune system is reacting to cancer, inflammation, or treatment.
Does the test help support immunotherapy?
Yes. The Immune Frame plays an important role in evaluating whether your immune system may respond well to immunotherapy. It assesses levels of key immune cells and signalling proteins to determine immune readiness and ongoing response during treatment. While it does not predict treatment success with certainty, it provides valuable data to guide decisions, monitor progress, and adjust treatment plans when necessary.
Is this test useful for specific types of cancer?
The test is suitable for patients with various cancer types, including breast cancer, colorectal cancer, and advanced cancer cases where immune function monitoring is essential. It does not diagnose cancer but can support personalised care once a diagnosis is made.
How is the test performed?
It is a non-invasive test that requires only a blood sample. This makes it simple and safe, unlike tissue biopsies. The sample is then analysed to evaluate your immune profile using cutting-edge molecular diagnostics.
Can the test help prevent cancer recurrence?
Yes. By monitoring immune response over time, the test helps detect potential weaknesses before a recurrence develops. This allows for timely intervention and adjustment of medical treatment strategies.
Does the test distinguish between healthy and cancerous cells?
The RGCC Immune Frame does not directly identify or label individual cells as healthy or cancerous. Instead, it evaluates how effectively your immune system can differentiate between normal and abnormal cell activity by measuring markers of immune activation and regulation. This helps guide immunotherapy and other treatments that rely on the immune system to selectively target tumour cells.
Are there any potential health risks involved in the test?
No. The test is safe and non-invasive. Since it only requires a blood draw, there are no known potential health risks associated with it.
Is this considered a cancer screening test?
The RGCC Immune Frame is not a cancer screening tool used to detect or diagnose cancer. Rather, it supports patients who already have a diagnosis by analysing immune performance and helping guide personalised treatment planning.
Can this test identify specific immune imbalances or vulnerabilities?
Yes. The Immune Frame is a test to identify specific immune system dysfunctions, such as low T-cell counts or abnormal cytokine levels. It also helps highlight immune system modulators that could be targeted to improve the body's response to cancer.
What kind of sample is required for this test?
The Immune Frame is performed using a standard blood test. This allows for a non-invasive yet highly detailed look into immune cell populations, cytokine profiles, and immune markers — all essential for evaluating your immune readiness in cancer care.
Does this test analyse gene expression?
The primary focus of the Immune Frame is on immune cell function and signalling molecules, such as cytokines. However, in some cases, the test may also provide insight into immune-related gene expression, particularly genes involved in inflammation, immune regulation, or tumour recognition. It is not a comprehensive gene expression profiling test but can offer additional information to support individualised treatment planning in cancer care.
How does the RGCC Immune Frame support cancer treatment planning?
The RGCC Immune Frame helps doctors treat cancer more effectively by identifying immune strengths, weaknesses, and inflammatory markers that influence treatment response. It supports targeted therapy by showing how well the immune system recognises abnormal cells and can inform decisions around immunotherapy strategies. While the test does not assess the primary tumor directly, it provides a systemic overview of immune activity in cancer patients.
Is the RGCC Immune Frame similar to a liquid biopsy test?
While it uses a blood sample like a liquid biopsy test, its purpose is different. Instead of detecting circulating tumor cells or tumour DNA, this test focuses on evaluating immune function. It offers complementary insights, especially for monitoring immune status during treatment and helping guide immune-based therapies.
Can this test support adoptive cell therapy or other immune-based treatments?
Yes. The Immune Frame is particularly valuable for patients considering adoptive cell therapy, such as T cell transfer therapy or protocols involving tumor infiltrating lymphocytes (TILs). It evaluates T-cell activity, cytokine signalling, and other immune markers to determine how well your body may respond to these advanced therapies. Although it doesn’t analyse normal cells or healthy cells directly, it does assess how effectively the immune system distinguishes between healthy and abnormal tissue.